Singapore’s Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab) for the prevention ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season. Paris, June 9, 2025. Sanofi is shipping Beyfortus starting in early Q3 to ...

Company planning for every eligible baby in the US to have access to BEYFORTUSNew BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...

(RTTNews) - Sanofi - Aventis Groupe said that the data featured at IDWeek from several national immunization programs will reinforce the proven efficacy and favorable safety profile of Beyfortus ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public ...

Company planning for every eligible baby in the US to have access to BEYFORTUSNew BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...

Company planning for every eligible baby in the US to have access to BEYFORTUSNew BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...

Thomas Grenier Head of Vaccines, North America, Sanofi "We're proud to offer BEYFORTUS doses to help protect every eligible baby in the US this RSV season. This accomplishment aimed at equitable ...